Trial reportBlood2007
Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection.
Trial report in Blood, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- B cell analysis in SARS-CoV-2 versus malaria: Increased frequencies of plasmablasts and atypical memory B cells in COVID-19.Journal of leukocyte biology · 2021Trial
- Article
- Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial.Viruses · 2021Review
- Comprehensive Review of HumanFrontiers in immunology · 2019Review
- Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice.Journal of virology · 2018Article
- Predicting HLA CD4 Immunogenicity in Human Populations.Frontiers in immunology · 2018Article
- Innate and Adaptive Immune Responses in Chronic HCV Infection.Current drug targets · 2017Review
- Article
- Anti-hepatitis C virus T-cell immunity in the context of multiple exposures to the virus.PloS one · 2015Article
- Immune control and failure in HCV infection--tipping the balance.Journal of leukocyte biology · 2014Review
- Selection of conserved epitopes from hepatitis C virus for pan-populational stimulation of T-cell responses.Clinical & developmental immunology · 2013Article
- Article
- Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+ T-cell immunity.European journal of immunology · 2012Article
- Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence.The Journal of experimental medicine · 2012Article
- Escape from a dominant HLA-B*15-restricted CD8+ T cell response against hepatitis C virus requires compensatory mutations outside the epitope.Journal of virology · 2012Article
- Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence.Immunologic research · 2010Review
- Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection.The Journal of general virology · 2010Article
- Prospective follow-up of patients with acute hepatitis C virus infection in Brazil.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2010Article
- Adaptive immunity to the hepatitis C virus.Advances in virus research · 2010Review
- Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope.Hepatology (Baltimore, Md.) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 3 countries.
Funding
Abstract
Chronic hepatitis C virus (HCV) infection is typically characterized by a lack of virus-specific CD4(+) T-cell-proliferative responses, but strong responses have been described in a subset of persons with persistent viremia. One possible explanation for these responses is that they were primed by an earlier resolved infection and do not recognize the current circulating virus. We defined all targeted epitopes using overlapping peptides corresponding to a genotype 1a strain in 44 patients chronically infected with different HCV genotypes (GT). Surprisingly, more HCV-specific CD4(+) T-cell responses were detected in patients with chronic non-GT1 infection compared with patients with chronic GT1 infection (P = .017). Notably, we found serologic evidence of a previous exposure to GT1 in 4 patients with non-GT1 infection, and these persons also demonstrated significantly more responses than non-GT1 patients in whom genotype and HCV serotype were identical (P < .001). Comparison of recognition of GT1-specific peptides to peptides representing autologous virus revealed the absence of cross-recognition of the autologous circulating virus. These data indicate that persistent HCV infection can occur in the presence of an HCV-specific T-cell response primed against a heterologous HCV strain, and suggest that clearance of 1 GT does not necessarily protect against subsequent exposure to a second GT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.